ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.300,39
0,06%
Dow Jones
39.961,93
0,23%
Euro vs US Dollar
1,0874
0,06%
Bitcoin
66.745,07
2,31%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Arrowhead Pharmaceuticals Inc (ARWR)

  7. Arrowhead Pharmaceuticals Inc (ARWR) News

ARWR

Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ARWR
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARWRArrowhead Pharmaceuticals Inc
07/05/202400h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
16/04/202415h00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:ARWRArrowhead Pharmaceuticals Inc
08/03/202423h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
06/03/202423h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
27/02/202423h08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARWRArrowhead Pharmaceuticals Inc
06/02/202422h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARWRArrowhead Pharmaceuticals Inc
06/02/202422h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARWRArrowhead Pharmaceuticals Inc
02/02/202423h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
31/01/202422h57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
26/01/202423h28Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ARWRArrowhead Pharmaceuticals Inc
18/01/202400h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
17/01/202423h22Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:ARWRArrowhead Pharmaceuticals Inc
17/01/202400h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
17/01/202400h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
17/01/202400h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
17/01/202400h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
12/01/202422h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
11/01/202422h48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
11/01/202422h38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
11/01/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
11/01/202422h05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
08/01/202423h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
08/01/202423h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
08/01/202423h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
06/01/202402h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
06/01/202401h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
05/01/202423h33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
05/01/202423h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
05/01/202422h58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARWRArrowhead Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ARWR

Kürzlich von Ihnen besucht

BOV
APTI4
ALIPERTI PN
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten